The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...

In 2023, experts decided against adding obesity drugs to the World Health Organisation's essential medicines list.

Viking is developing what might be a game-changing medication in the segment. Viking Therapeutics (NASDAQ: VKTX), a biotech ...

The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new study published Wednesday.

The Food and Drug Administration accepted Novo Nordisk’s marketing application for an oral version of its weight-loss drug Wegovy and will decide in the fourth quarter, the Danis ...

Novo Nordisk (NYSE:NVO) shares climbed 5.4% Friday after the U.S. Food and Drug Administration accepted the company’s New Drug Application for an oral version of Wegovy. If approved, the pill ...

Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease ...

More than a billion people now have obesity worldwide, according to the WHO, and around 70% of them live in low and ...

Anthropic is preparing to carry out its first employee share buyback, valuing the firm at $61.5 billion. The initiative also ...

The stock market ended the trading week on a strong note, with all major indices clocking in strong gains, as investors cheered better-than-expected non-farm payrolls last month while digesting more ...

NEW YORK CITY, NY / ACCESS Newswire / May 2, 2025 / In an era where healthcare is as much about timely access and ...